A Clinical Follow-up Study of Heart Failure Patients.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03797742

Enrollment

500

Registered

2019-01-09

Start date

2018-01-01

Completion date

2022-12-01

Last updated

2019-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Heart failure (HF), a current worldwide pandemic with an unacceptable high level of morbidity and mortality, brings an enormous medical and societal burden. Chronic HF is characterized by progressive alteration of cardiac structure and function. But the molecular mechanism of these alterations is still not well-established and needs to be discussed further. HF is a highly heterogeneous disease that can be caused by a multiple of diseases. Dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) are the main causes of this syndrome. Although HF is the common manifestation of DCM and ICM, the etiology and pathogenesis are different. Understanding the different pathophysiological mechanisms will contribute to the prevention and individualized therapy of heart failure. Therefore, this study aims to observation the different characteristics of the molecular biology and clinical courses in DCM and ICM patients.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

15 Years to 80 Years

Healthy volunteers

Inclusion criteria

* LVEF≤ 55% * enlarged left ventricular end-diastolic dimension * ICM group: with history of MI or revascularization; ≥ 75% stenosis of LM or proximal LAD; ≥ 75% stenosis of two or more epicardial vessels. * symptomatic heart failure

Exclusion criteria

* Known malignant tumour diseases * Pregnancy or lactation period； * Investigators think not suitable to participate in this trial.

Design outcomes

Primary

Measure	Time frame	Description
NYHA functional class	one year after enrolled	NYHA cardiac functional class
All-cause mortality	one year after enrolled	All-cause mortality during follow-up

Secondary

Measure	Time frame	Description
hospitalization for cardiac causes	one year after enrolled	hospitalization for cardiac causes during follow-up
left ventricular end-diastolic dimension(LVEDD) dilates.	one year after enrolled	left ventricular structure changes:left ventricular end-diastolic dimension(LVEDD) dilates.
left ventricular ejection fraction reduces	one year after enrolled	left ventricular function changes:left ventricular ejection fraction reduces

Countries

China

Contacts

Primary ContactZhangwei Chen

chen.zhangwei@zs-hospital.sh.cn+86 021 64041990

Outcome results